213 related articles for article (PubMed ID: 33838058)
1. CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function.
Whiteside SK; Grant FM; Gyori DS; Conti AG; Imianowski CJ; Kuo P; Nasrallah R; Sadiyah F; Lira SA; Tacke F; Eil RL; Burton OT; Dooley J; Liston A; Okkenhaug K; Yang J; Roychoudhuri R
Immunology; 2021 Aug; 163(4):512-520. PubMed ID: 33838058
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic depletion of CCR8
Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
[TBL] [Abstract][Full Text] [Related]
3. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory.
Kidani Y; Nogami W; Yasumizu Y; Kawashima A; Tanaka A; Sonoda Y; Tona Y; Nashiki K; Matsumoto R; Hagiwara M; Osaki M; Dohi K; Kanazawa T; Ueyama A; Yoshikawa M; Yoshida T; Matsumoto M; Hojo K; Shinonome S; Yoshida H; Hirata M; Haruna M; Nakamura Y; Motooka D; Okuzaki D; Sugiyama Y; Kinoshita M; Okuno T; Kato T; Hatano K; Uemura M; Imamura R; Yokoi K; Tanemura A; Shintani Y; Kimura T; Nonomura N; Wada H; Mori M; Doki Y; Ohkura N; Sakaguchi S
Proc Natl Acad Sci U S A; 2022 Feb; 119(7):. PubMed ID: 35140181
[TBL] [Abstract][Full Text] [Related]
4. Acquisition of suppressive function by conventional T cells limits antitumor immunity upon T
Whiteside SK; Grant FM; Alvisi G; Clarke J; Tang L; Imianowski CJ; Zhang B; Evans AC; Wesolowski AJ; Conti AG; Yang J; Lauder SN; Clement M; Humphreys IR; Dooley J; Burton O; Liston A; Alloisio M; Voulaz E; Langhorne J; Okkenhaug K; Lugli E; Roychoudhuri R
Sci Immunol; 2023 Dec; 8(90):eabo5558. PubMed ID: 38100544
[TBL] [Abstract][Full Text] [Related]
5. CCR8
Barsheshet Y; Wildbaum G; Levy E; Vitenshtein A; Akinseye C; Griggs J; Lira SA; Karin N
Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6086-6091. PubMed ID: 28533380
[TBL] [Abstract][Full Text] [Related]
6. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models.
Campbell JR; McDonald BR; Mesko PB; Siemers NO; Singh PB; Selby M; Sproul TW; Korman AJ; Vlach LM; Houser J; Sambanthamoorthy S; Lu K; Hatcher SV; Lohre J; Jain R; Lan RY
Cancer Res; 2021 Jun; 81(11):2983-2994. PubMed ID: 33757978
[TBL] [Abstract][Full Text] [Related]
7. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
[TBL] [Abstract][Full Text] [Related]
8. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
9. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Cohen AD; Schaer DA; Liu C; Li Y; Hirschhorn-Cymmerman D; Kim SC; Diab A; Rizzuto G; Duan F; Perales MA; Merghoub T; Houghton AN; Wolchok JD
PLoS One; 2010 May; 5(5):e10436. PubMed ID: 20454651
[TBL] [Abstract][Full Text] [Related]
10. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
[TBL] [Abstract][Full Text] [Related]
11. In situ analysis of CCR8
Hayashi Y; Ueyama A; Funaki S; Jinushi K; Higuchi N; Morihara H; Hirata M; Nagira Y; Saito T; Kawashima A; Iwahori K; Shintani Y; Wada H
BMC Cancer; 2024 May; 24(1):627. PubMed ID: 38783281
[TBL] [Abstract][Full Text] [Related]
12. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.
Kimpfler S; Sevko A; Ring S; Falk C; Osen W; Frank K; Kato M; Mahnke K; Schadendorf D; Umansky V
J Immunol; 2009 Nov; 183(10):6330-7. PubMed ID: 19841169
[TBL] [Abstract][Full Text] [Related]
13. CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer.
Wang T; Zhou Q; Zeng H; Zhang H; Liu Z; Shao J; Wang Z; Xiong Y; Wang J; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Chang Y; Wang X; Xu J
Cancer Immunol Immunother; 2020 Sep; 69(9):1855-1867. PubMed ID: 32367308
[TBL] [Abstract][Full Text] [Related]
14. Suppressive IL-17A
Downs-Canner S; Berkey S; Delgoffe GM; Edwards RP; Curiel T; Odunsi K; Bartlett DL; Obermajer N
Nat Commun; 2017 Mar; 8():14649. PubMed ID: 28290453
[TBL] [Abstract][Full Text] [Related]
15. Absence of amplification of CD4+CD25(high) regulatory T cells during in vitro expansion of tumor-infiltrating lymphocytes in melanoma patients.
Knol AC; Lemaître F; Pandolfino MC; Volteau C; Quéreux G; Saiagh S; Khammari A; Viguier M; Dréno B
Exp Dermatol; 2008 May; 17(5):436-45. PubMed ID: 18312383
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody.
Weaver JD; Stack EC; Buggé JA; Hu C; McGrath L; Mueller A; Wong M; Klebanov B; Rahman T; Kaufman R; Fregeau C; Spaulding V; Priess M; Legendre K; Jaffe S; Upadhyay D; Singh A; Xu CA; Krukenberg K; Zhang Y; Ezzyat Y; Saddier Axe D; Kuhne MR; Meehl MA; Shaffer DR; Weist BM; Wiederschain D; Depis F; Gostissa M
Oncoimmunology; 2022; 11(1):2141007. PubMed ID: 36352891
[TBL] [Abstract][Full Text] [Related]
17. Bcl6 Preserves the Suppressive Function of Regulatory T Cells During Tumorigenesis.
Li Y; Wang Z; Lin H; Wang L; Chen X; Liu Q; Zuo Q; Hu J; Wang H; Guo J; Xie L; Tang J; Li Z; Hu L; Xu L; Zhou X; Ye L; Huang Q; Xu L
Front Immunol; 2020; 11():806. PubMed ID: 32477338
[TBL] [Abstract][Full Text] [Related]
18. Blocking retinoic acid receptor-α enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells.
Galvin KC; Dyck L; Marshall NA; Stefanska AM; Walsh KP; Moran B; Higgins SC; Dungan LS; Mills KH
Cancer Immunol Immunother; 2013 Jul; 62(7):1273-82. PubMed ID: 23657628
[TBL] [Abstract][Full Text] [Related]
19. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
Klages K; Mayer CT; Lahl K; Loddenkemper C; Teng MW; Ngiow SF; Smyth MJ; Hamann A; Huehn J; Sparwasser T
Cancer Res; 2010 Oct; 70(20):7788-99. PubMed ID: 20924102
[TBL] [Abstract][Full Text] [Related]
20. T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3.
Quatromoni JG; Morris LF; Donahue TR; Wang Y; McBride W; Chatila T; Economou JS
J Hematol Oncol; 2011 Nov; 4():48. PubMed ID: 22112546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
